+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Frontiers in Cardiovascular Drug Discovery: Volume 5

  • ID: 5188259
  • Book
  • October 2020
  • Bentham Science Publishers Ltd
1 of 3
Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The book series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology.

The fifth volume of the series covers the following topics:
  • The Lipid Hypothesis: From Resins to Proprotein Convertase Subtilisin/Kexin Type-9 Inhibitors
  • The Role of SGLT2i in the Prevention and Treatment of Heart Failure
  • Natural Products and Semi-Synthetic Compounds as Antithrombotics: A Review of the Last Ten Years (2009-2019)
  • Transient Receptor Potential Channels: Therapeutic Targets for Cardiometabolic Diseases?
  • Treatment of Raynaud’s Phenomenon
  • Traditional Medicine Based Cardiovascular Therapeutics
  • Cardiovascular Disease: A Systems Biology Approach
Note: Product cover images may vary from those shown
2 of 3

Chapter 1 The Lipid Hypothesis: from Resins to Proprotein Convertase

  • Subtilisin/Kexin Type-9 Inhibitors
  • Sudarshan Ramachandran, Mithun Bhartia and Carola S. König
  • Introduction
  • Cholesterol
  • Early Evolution of the Relationship Between Cholesterol and Atherogenesis
  • Longitudinal Prospective Observational Studies and Cvd Risk
  • Algorithms
  • Interventional Studies with Clinical Events as Outcomes
  • Randomised Controlled Bile Sequestrants Trials
  • Randomised Controlled Statin Trials
  • Randomised Controlled Ezetimibe Trials
  • Randomised Controlled Pcsk9 Inhibitor Trials
  • The Recent Case Against the Lipid Hypothesis
  • Role of Other Lipid Lowering Agents
  • Role of Anti-Inflammatory Therapy
  • Refining the Lipid Hypothesis: Identification of Subgroups
  • Demonstrating Even Greater Benefit
  • Conclusion
  • Disclosure Statement
  • Consent for Publication
  • Conflict of Interest
  • Acknowledgements
  • References

Chapter 2 The Role of Sglt2I in the Prevention and Treatment of Heart Failure

  • Hasan Alturki, Ahmed Alturki, Mark Sherman, Abhinav Sharma and Thao
  • Huynh
  • Introduction
  • Heart Failure
  • Mechanisms of Action of Sglt2 and Sgtl2I
  • Glucose Homeostasis
  • Cardiovascular Effects of Sglt2I
  • Nephroprotective Effects of Sglt2I
  • Cv Outcomes in Patients with T2Dm
  • Renal Outcomes in Patients with T2Dm and Chronic Kidney Disease (Ckd)
  • Heart Failure
  • Peripheral Arterial Disease
  • Acute Heart Failure
  • Real-World Data
  • Current Sglt2I Uses
  • Current Use of Sglt2 Inhibitors in Clinical Practice
  • Practical Considerations with Sglt2I Prescription
  • Future Directions and Ongoing Trials
  • Conclusions
  • Consent for Publication
  • Conflicts of Interest
  • Acknowledegements
  • References

Chapter 3 Natural Products and Semi-Synthetic Compounds As

  • Antithrombotics: a Review of the Last Ten Years (2009-2019)
  • Angelo Piato and Cedric Stephan Graebin
  • Introduction
  • Natural Products with Antithrombotic Activity
  • Antithrombotic Molecules Obtained from Marine-Based Sources
  • Antithrombotics from Microorganisms
  • Antithrombotics from Plant-Based Sources
  • Semi-Synthetic Compounds with Antithrombotic Activity
  • Conclusion
  • Abbreviations
  • Consent for Publication
  • Conflict of Interest
  • Acknowledgement
  • References

Chapter 4 Transient Receptor Potential Channels: Therapeutic

  • Targets for Cardiometabolic Diseases?
  • Leidyanne Ferreira Gonçalves, Thereza Cristina Lonzetti Bargut and Caroline Fernandes-
  • Santos
  • Introduction
  • Trp Channels
  • Trpa (Ankyrin) Family
  • Trpc (Canonical) Family
  • Trpm (Melastatin) Family
  • Trpml (Mucolipin) Family
  • Trpp (Polycystin) Family
  • Trpv (Vanilloid) Family
  • Trp Channels and Cardiovascular Diseases
  • Trp Expression
  • Trpa1
  • Trpc
  • Trpm
  • Trpv
  • Evidence of Trp Modulation in the Cardiovascular System
  • Trpc
  • Trpv
  • Doxorubicin-Induced Cardiotoxicity
  • Obesity and Diabetes
  • Trp Expression
  • Trpa1
  • Trpc
  • Trpm
  • Trpml and Trpp
  • Trpv
  • Modulation of Trp Expression in the Adipose Tissue and Endocrine Pancreas
  • Trpa1
  • Trpc
  • Trpm
  • Trpv
  • Future Perspectives
  • Conclusion
  • Consent for Publication
  • Conflict of Interest
  • Acknowledgements
  • References

Chapter 5 Treatment of Raynaud's Phenomenon

  • Sevdalina Nikolova Lambova
  • Primary Raynaud's Phenomenon
  • Ginkgo Biloba
  • Pharmacology
  • Clinical Trials
  • Secondary Raynaud's Phenomenon in Systemic Sclerosis
  • Calcium Channel Blockers
  • Pharmacology
  • Clinical Data
  • Safety Profile
  • Pentoxifyllin
  • Pharmacology
  • Clinical Data
  • Safety Profile
  • Nitric Oxide Pathway
  • Phosphodiesterase-5 Enzyme Inhibitors
  • Topical Glyceryl Trinitrate
  • Prostacyclin Pathway
  • Iloprost
  • Epoprostenol
  • Prostaglandin E1 (Alprostadil)
  • Treprostinil
  • Oral Prostanoids
  • Serotonin Inhibition - Fluoxetine
  • Pharmacology
  • Clinical Data and Safety Profile
  • Endothelin Pathway and Endothelin-Receptor Antagonists
  • Endothelin Pathway
  • Clinical Data
  • Safety Profile
  • Renin-Angiotensin System
  • Angiotensin Ii Receptor Blocker - Losartan
  • Angiotensin-Converting Enzyme Inhibitors
  • Alpha-Adrenergic Blockers
  • Prazosin
  • Alpha-2C Adrenergic Receptor Antagonists
  • Statins
  • Pharmacology
  • Clinical Data
  • Safety Profile
  • Antiplatelet Therapy and Anticoagulants
  • Treatment of Digital Ulcers in Severe Rp in Ssc
  • Combination Therapy in Severe Peripheral Vascular Syndrome with Digital Ulcers in Ssc
  • Other Treatments
  • Botulinum Toxin
  • Rho-Kinase Inhibitors
  • Conclusion
  • Conflict of Interest
  • Acknowledgements
  • References

Chapter 6 Traditional Medicine Based Cardiovascular Therapeutics

  • Sriram Kumar, Rekha Ravindran, Sakthi Abbirami Gowthaman, Sujata Roy and Johanna
  • Rajkumar
  • Introduction
  • Cardiovascular Diseases
  • Pathophysiology of Cvd
  • Different Types of Cvd
  • Indian Cardiovascular Therapeutics
  • Ambrex
  • Abana
  • Arjunarishta
  • Arogh
  • Bhux
  • Lipistat
  • Liposem
  • Marutham
  • Triglize
  • Traditional Chinese Medicine
  • Bushen Kangle
  • Dang Gui Long Hui Wan
  • Er Chen Wan
  • Fu Fang Dan Shen
  • Fu Fang GE Qing
  • Jiang Zhi Ling
  • Jin Kui Shen Qi Wan
  • Ke Chuan
  • Qing Nao Jiang Ya
  • Sheng Mai Yin
  • Su He Xiang Wan
  • Tian Wang Bu Xin Dan
  • Tong Xin Luo
  • Xie Qing Wan
  • Xin Bao Wan
  • Yang Xin Yin
  • Informatics in Cvdd
  • Herboinformatics in Cvdd
  • Pharmacoinformatics in Cvdd
  • Toxicoinformatics in Cvdd
  • Cellular Models for In-Vitro Research
  • Human Cardiac Myocytes
  • Human Aortic Endothelial Cells
  • Human Coronary Artery Endothelial Cells
  • Human Pulmonary Artery Endothelial Cells
  • Human Cardiac Microvascular Endothelial Cells
  • Human Pulmonary Microvascular Endothelial Cells
  • Human Dermal Microvascular Endothelial Cells
  • Conclusion
  • Conflict of Interest
  • Acknowledgement
  • References

Chapter 7 Cardiovascular Disease: a Systems Biology Approach

  • Sujata Roy and Ashasmita S Mishra
  • Introduction
  • Cell-Based Cardiac Disease Models and Animal Models
  • Post-Genomic Era and Systems Biology Concept
  • Systems Biology
  • What is a Network and How to Construct?
  • From Network to Modules and Models
  • Systems Genetics
  • Genomic Study and Genome-Wide Association in Cardiovascular Traits
  • Systems Medicine
  • Integrative Biology
  • Disease Comorbities and Network Biology
  • Tools and Databases
  • Public Data Sources, Prior Knowledge, and Data Integration
  • Conclusion
  • Consent for Publication
  • Conflict of Interest
  • Acknowledgements
  • References
  • Subject Index
Note: Product cover images may vary from those shown
3 of 3
  • Atta-ur-Rahman
  • M. Iqbal Choudhary
Note: Product cover images may vary from those shown
Adroll
adroll